Literature DB >> 27871116

Glucocorticoid Signaling and Bone Biology.

T Komori1.   

Abstract

Since glucocorticoids remain an effective therapeutic option for the treatment of many inflammatory and autoimmune diseases, glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. Fractures may occur in as many as 30-50% of patients receiving chronic glucocorticoid therapy. Under physiological conditions, glucocorticoids are required for normal bone development due to their regulation of osteoblast differentiation, possibly via the Wnt/β-catenin pathway and TSC22D3. However, serum levels of endogenous corticosterone are elevated in aged mice and glucocorticoids exert negative effects on the survival of osteoblasts and osteocytes as well as angiogenesis. Glucocorticoid treatments impair bone formation and enhance bone resorption. Excess glucocorticoids induce osteoblast and osteocyte apoptosis by increasing pro-apoptotic molecules, reactive oxygen species, and endoplasmic reticulum stress and suppressing the Wnt/β-catenin pathway. Autophagy protects osteocytes from glucocorticoid-induced apoptosis, but passed some threshold, the process of autophagy leads the cells to apoptosis. Excess glucocorticoids impair osteoblastogenesis by inducing Wnt antagonists, including Dkk1, Sost, and sFRP-1. However, the findings are controversial and the involvement of Wnt antagonists requires further study. Excess glucocorticoids reduce the phosphorylation of Akt and GSK3β, which enhances the degradation of β-catenin. Excess glucocorticoids have been shown to modulate the expression of miRNAs, including miR-29a, miR-34a-5p, and miR-199a-5p, which regulate the proliferation and differentiation of osteoblast lineage cells. Excess glucocorticoids also enhance bone resorption by reducing OPG expression, increasing Rankl expression and reactive oxygen species, and prolonging the life span of osteoclasts; however, they also suppress the bone-degrading capacity of osteoclasts by disturbing the organization of the cytoskeleton. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27871116     DOI: 10.1055/s-0042-110571

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  36 in total

Review 1.  The roles of Orai and Stim in bone health and disease.

Authors:  Lisa J Robinson; Harry C Blair; John B Barnett; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2019-06-05       Impact factor: 6.817

2.  Chronic Corticosterone Treatment During Adolescence Has Significant Effects on Metabolism and Skeletal Development in Male C57BL6/N Mice.

Authors:  Scott A Kinlein; Ziasmin Shahanoor; Russell D Romeo; Ilia N Karatsoreos
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

Review 3.  Osteoporosis: what the clinician needs to know?

Authors:  Rosario Francesco Balzano; Maria Mattera; Xiaoguang Cheng; Samantha Cornacchia; Giuseppe Guglielmi
Journal:  Quant Imaging Med Surg       Date:  2018-02

Review 4.  Advances in treatment of glucocorticoid-induced osteoporosis.

Authors:  Emory Hsu; Mark Nanes
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-12       Impact factor: 3.243

5.  Glucagon-like peptide 2 decreases osteoclasts by stimulating apoptosis dependent on nitric oxide synthase.

Authors:  Yi Lu; Dongdong Lu; Yu Hu
Journal:  Cell Prolif       Date:  2018-02-19       Impact factor: 6.831

6.  Intraarticular injection of dexamethasone promotes bone erosion in collagen-induced arthritis in mice through up-regulation of RANKL expression.

Authors:  Xiaoxuan Sun; Yanyan Wang; Miaojia Zhang; Qiang Wang
Journal:  Inflammopharmacology       Date:  2018-10-20       Impact factor: 4.473

7.  Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in humans.

Authors:  Z E Belaya; T A Grebennikova; G A Melnichenko; A G Nikitin; A G Solodovnikov; O I Brovkina; A U Grigoriev; L Y Rozhinskaya; I I Dedov
Journal:  Osteoporos Int       Date:  2017-10-04       Impact factor: 4.507

8.  Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia.

Authors:  Jinhui Ma; Kerry Siminoski; Nathalie Alos; Jacqueline Halton; Josephine Ho; Elizabeth A Cummings; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; Jacob L Jaremko; Beverly Wilson; David Stephure; Robert Stein; Anne Marie Sbrocchi; Celia Rodd; Victor A Lewis; Caroline Laverdière; Sara Israels; Ronald M Grant; Conrad V Fernandez; David B Dix; Robert Couch; Elizabeth Cairney; Ronald Barr; Stephanie Atkinson; Sharon Abish; David Moher; Frank Rauch; Leanne M Ward
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

9.  Sialic acid-modified solid lipid nanoparticles as vascular endothelium-targeting carriers for ischemia-reperfusion-induced acute renal injury.

Authors:  Jing-Bo Hu; Gui-Ling Song; Di Liu; Shu-Juan Li; Jia-Hui Wu; Xu-Qi Kang; Jing Qi; Fei-Yang Jin; Xiao-Juan Wang; Xiao-Ling Xu; Xiao-Ying Ying; Lian Yu; Jian You; Yong-Zhong Du
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.819

10.  Age-dependent modulation of bone metabolism in zebrafish scales as new model of male osteoporosis in lower vertebrates.

Authors:  Marta Carnovali; Giuseppe Banfi; Massimo Mariotti
Journal:  Geroscience       Date:  2020-09-30       Impact factor: 7.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.